Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fase 2-studie til vurdering af sikkerhed og effekt af ANG003

29. oktober 2026 opdateret af: Anagram Therapeutics, Inc.

En fase 2, multicenter, randomiseret, aktiv-kontrolleret undersøgelse for at vurdere sikkerheden og effektiviteten af ANG003 ved to forskellige doseringsniveauer hos personer med exokrin pankreasinsufficiens på grund af cystisk fibrose

In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

113

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • California
      • Long Beach, California, Forenede Stater, 90806
        • Rekruttering
        • Long Beach Memorial Medical Center
        • Kontakt:
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • Center for Cystic Fibrosis at Keck Medical Center of USC
        • Kontakt:
    • Colorado
      • Denver, Colorado, Forenede Stater, 80206
        • Rekruttering
        • National Jewish Health
        • Kontakt:
    • Florida
      • Gainesville, Florida, Forenede Stater, 32610
        • Ikke rekrutterer endnu
        • University of Florida
        • Kontakt:
      • Orlando, Florida, Forenede Stater, 32803
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30324
        • Rekruttering
        • Emory-Children's Healthcare of Atlanta Cystic Fibrosis Center
        • Kontakt:
    • Illinois
      • Glenview, Illinois, Forenede Stater, 60025
        • Rekruttering
        • The Cystic Fibrosis Institute
        • Kontakt:
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Ikke rekrutterer endnu
        • University of Iowa
        • Kontakt:
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • Rekruttering
        • University of Kansas Medical Center
        • Kontakt:
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40506
        • Rekruttering
        • University of Kentucky
        • Kontakt:
    • Maine
      • Portland, Maine, Forenede Stater, 04102
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
        • Kontakt:
      • Boston, Massachusetts, Forenede Stater, 02115
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Rekruttering
        • University of Michigan, Michigan Medicine
        • Kontakt:
      • Detroit, Michigan, Forenede Stater, 48201
        • Rekruttering
        • Wayne State University Harper University Hospital
        • Kontakt:
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • Rekruttering
        • University of Minnesota
        • Kontakt:
          • Brooke Noren, RN, BSN, CCRC
          • Telefonnummer: 612-625-7995
          • E-mail: boer0039@umn.edu
    • New Jersey
      • New Brunswick, New Jersey, Forenede Stater, 08903
        • Rekruttering
        • Rutgers - Robert Wood Johnson Medical School
        • Kontakt:
    • New York
      • Valhalla, New York, Forenede Stater, 10595
        • Ikke rekrutterer endnu
        • New York Medical College at Westchester Medical Center
        • Kontakt:
    • Ohio
      • Akron, Ohio, Forenede Stater, 44308
        • Rekruttering
        • Children's Hospital Medical Center of Akron
        • Kontakt:
      • Cleveland, Ohio, Forenede Stater, 44106
        • Rekruttering
        • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
        • Kontakt:
      • Columbus, Ohio, Forenede Stater, 43205
      • Toledo, Ohio, Forenede Stater, 43606
        • Rekruttering
        • Toledo Children's Hospital
        • Kontakt:
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Rekruttering
        • Hershey Medical Center Pennsylvania State University
        • Kontakt:
      • Pittsburgh, Pennsylvania, Forenede Stater, 15224
        • Ikke rekrutterer endnu
        • University of Pittsburgh Medical Center
        • Kontakt:
    • Texas
      • Dallas, Texas, Forenede Stater, 75207
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Rekruttering
        • Adult Cystic Fibrosis Center at the University of Utah
        • Kontakt:
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Ikke rekrutterer endnu
        • Froedtert & Medical College of Wisconsin
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male and female subjects aged ≥12 years from the date of informed consent in the US and aged ≥18 years in the EU

  2. Confirmed and documented diagnosis of CF

  3. Diagnosed with severe EPI as defined by a fecal elastase ≤50 μg/g stool measured at Screening by a central laboratory.

  4. Subject has controlled EPI and taking a stable dose of pancreatic enzyme replacement therapy (PERT) for 90 days prior to Screening.

  5. Adequate nutritional status measured by body mass index (BMI) defined by:

    1. BMI ≥25th percentile for children aged 12-17 years
    2. BMI ≥18.5 kg/m2 for ≥18 years of age

Exclusion Criteria:

  1. History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of Screening.
  2. History of lung or liver transplant, listing for organ transplant or significant bowel resection within the last 6 months. Subjects with a history of resection that does not result in short bowel syndrome are eligible.
  3. Known hypersensitivity or other severe reaction to any ingredient of the investigational product (IP), Creon, or the stool marker (FD&C Blue #2).
  4. Any chronic diarrheal illness unrelated to pancreatic insufficiency, actively being treated for small intestinal bacterial overgrowth, requiring use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study duration, Clostridioides difficile infection within 6 months prior to Screening, or severe constipation defined as <1 bowel movement/week.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ANG003 Dose A

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose A for a 21-day acclimation and subsequent CFA analysis.

160,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP])

Eksperimentel: ANG003 Dose B

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose B for a 21-day acclimation and subsequent CFA analysis.

240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP])

Aktiv komparator: Creon

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to Creon for an additional 21-days and subsequent CFA analysis.

The commercially available pPERT Creon will be the active comparator in the study. Subjects will be instructed to take Creon according to the package insert and PI direction.

Ingen indgriben: Off Enzyme

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to the off enzyme arm. Subjects will receive Creon for an additional 21-day and the subsequent CFA analysis will be off enzyme. Total time off enzyme will be 4-7 days.

Andet: 60% to <80% CFA ANG003 Dose B

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. Participants with a Period A CFA result of 60% to <80% will be assigned to ANG003 Dose B.

240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP])

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values
Tidsramme: From Visit 1 to Visit 5, anticipated average 80 days

Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values

From Visit 1 to Visit 5, anticipated average 80 days
Coefficient of Fat Absorption (CFA)
Tidsramme: Period A (baseline) and Period B 72 hour CFA collection

Mean change from baseline CFA (i.e., Period B CFA minus Period A CFA) assessed for ANG003 Dose A, ANG003 Dose B, and Creon amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B 72 hour CFA collection

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Plasma docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (ug/mL)
Tidsramme: Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
Coefficient of Nitrogen Absorption (CNA)
Tidsramme: Period A (baseline) and Period B 72 hour CNA collection

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B 72 hour CNA collection
% of subjects with GI symptoms
Tidsramme: From Visit 2 to Visit 5, anticipated average 59 days

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

From Visit 2 to Visit 5, anticipated average 59 days
Cumulative stool weight
Tidsramme: Period A (baseline) and Period B 72 hour collection

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B 72 hour collection
Number of Stools per Day
Tidsramme: Period A (baseline) and Period B 72 hour collection

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B 72 hour collection

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Correlation between DHA/EPA and CFA
Tidsramme: Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection

Mean change from baseline for each treatment group with a baseline CFA ≥80%

Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
Coefficient of Fat Absorption (CFA) for subjects with a baseline CFA of 60% to <80% (analyzed separately)
Tidsramme: Period A (baseline) and Period B 72 hour CFA collection

Mean change from baseline for each treatment group with a baseline CFA 60% to <80%

Period A (baseline) and Period B 72 hour CFA collection
Mean Period B CFA for all subjects randomized to the Off Enzyme arm with a baseline CFA ≥80%
Tidsramme: Period B 72 hour CFA collection

Period B CFA Off Enzyme in subjects with a baseline CFA ≥80%

Period B 72 hour CFA collection

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. april 2026

Primær færdiggørelse (Anslået)

1. juli 2027

Studieafslutning (Anslået)

1. juli 2027

Datoer for studieregistrering

Først indsendt

9. februar 2026

Først indsendt, der opfyldte QC-kriterier

26. februar 2026

Først opslået (Faktiske)

4. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner